Generics 19

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Atracurium besylate manufacturers

19 products found

Filters

19 products found

atracurium besylate

Ampoules, injection 10 mg/ml - 2.5 ml, 5 ml, 10 ml

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP
Available for
Licensing with supply, Distribution only
Manufacturer #18885

Manufacturer usually replies in 7 days

atracurium besylate

Injection 50 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Indonesia
GMP approvals
Indonesia
Manufacturer #20700

Manufacturer usually replies in 5 days

atracurium besylate

Injection 10 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Indonesia
GMP approvals
Indonesia
Manufacturer #20656

Manufacturer usually replies in 2 days

atracurium besylate

Vials 10 mg/ml

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
GMP, WHO
Manufacturer #24869

Manufacturer usually replies in 3 days

atracurium besylate

Injection 10 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #20087

Manufacturer usually replies in 8 days

atracurium besylate

Injection 10 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #20368

Manufacturer usually replies in 8 days

atracurium besylate

Injection 25 mg, 50 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #18256

Manufacturer usually replies in 6 days

atracurium besylate

Injection 25 mg / 2.5 ml, 100 mg / 10 ml, 50 mg / 5 ml

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #17417

Manufacturer usually replies in 6 days

atracurium besylate

Solution for injection 10 mg / 1 ml

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Ukraine
GMP approvals
PICS
Manufacturer #17328
It is established in the 1990s. The main purpose of the company is to produce high-quality infusion and injection solutions that are being used during emergency medical and intensive care. The company includes production with a system of sterilized premises, up-to-date technologies, and equipment from leading European producers. The company has its manufacturing base and well-equipped laboratories. Manufacturing and supervision processes are provided by highly qualified personnel: technologists, microbiologists, and analytical chemists.

Manufacturer usually replies in 8 days

atracurium besylate

Ampoules, injection 10mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Egypt
GMP approvals
WHO
Manufacturer #16140

Manufacturer usually replies in 8 days

atracurium besylate

Solution for injection 10mg/ml

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Available for
Licensing with supply
Manufacturer #10323

Manufacturer usually replies in 5 days

atracurium besylate

Solution for injection 25/50 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO, INVIMA
Manufacturer #10726

Manufacturer usually replies in 7 days

atracurium besylate

Ampoules, injection 10 mg/ml - 20 ml

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Indonesia
GMP approvals
WHO
Unavailable markets
Philippines
Manufacturer #559

Manufacturer usually replies in 8 days

atracurium besylate

Injection 10mg/5ml,20mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
China
GMP approvals
EU GMP
Manufacturer #8101

Manufacturer usually replies in 29 days

atracurium besylate

Injection 10 MG

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #19051

Manufacturer usually replies in 14 days

atracurium besylate

Ampoules, injection 10 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #19051

Manufacturer usually replies in 14 days

atracurium besylate

Ampoules, injection 50 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Egypt
GMP approvals
FDA
Manufacturer #21935

Manufacturer usually replies in 35 days

atracurium besylate

Injection 10 mg, 25 mg, 50 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #19912

Manufacturer usually replies in 18 days

atracurium besylate

Ampoules, injection 25 mg/2.5 ml, 50 mg/5 ml

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Turkey
GMP approvals
PICS
Manufacturer #1430

Manufacturer usually replies in nan days

What is ATRACURIUM BESYLATE?

ATRACURIUM BESYLATE is an intermediate-duration, nondepolarizing, skeletal muscle relaxant. It works in intravenous terms. It is a complex molecule that contains four sites at which unusual stereochemical configurations can happen. The balance of the molecule, nonetheless, appears in only ten, rather than sixteen, tolerable another isomer. The production of this pharmaceutical substance issues in these isomers being produced in ill-matched amounts but with a regular ratio. Those molecules in which the methyl group attached to the quaternary nitrogen projects on the side to the adjacent substituted-benzyl moiety predominate by almost 3:1. TRACRIUM is an injection form of this pharmaceutical medicine is a sterile, nonpyrogenic aqueous solution. Each mL contains 10 mg atracurium besylate. The pH is balanced to 3.25 to 3.65 including benzenesulfonic acid. The multiple-dose vial contains 0.9% benzyl liquor combined as prophylaxis. This pharmaceutical drug gradually loses potency with time at the rate of around 6% per year under freezing (5° C). This pharma medicine is an Injection that should be cooled at 2° to 8° C (36° to 46° F) to preserve potency. The rate of loss in potency increases to approximately 5% per month at 25° C (77° F). Simultaneous departure from refrigeration to room temperature storage conditions (25° C/ 77° F), it is recommended employment TRACRIUM (atracurium besylate) Injection within 14 days, even if refrigerated. TRACRIUM (atracurium besylate) is registered, as a supplement to general stupor, to promote endotracheal intubation and to render skeletal muscle leisure during surgery or mechanical air-conditioning. Dosage reductions must be considered also in patients with neuromuscular disease, severe electrolyte disorders, or carcinomatosis in which potentiation of neuromuscular block or difficulties with reversal have been demonstrated. There has been no clinical experience with TRACRIUM (atracurium besylate) in these patients, and no specific dosage adjustments can be recommended. No dosage adjustments of TRACRIUM (atracurium besylate) are required for patients with renal disease.

How does ATRACURIUM BESYLATE work?

It is a pharmaceutical substance that helps to antagonizes the neurotransmitter action of acetylcholine by securing competitively with the cholinergic receptor places on the motor end-plate. This opposition is frustrated, and neuromuscular block reversed, by acetylcholinesterase inhibitors before-mentioned neostigmine, edrophonium, and pyridostigmine.

The Wholesale Price of ATRACURIUM BESYLATE

The cost for atracurium intravenous solution (10 mg/mL) is around $49 for a supply of 50 milliliters, depending on the pharmacy you visit. Prices of this product substance may vary from on the store you visit.

Sourcing ATRACURIUM BESYLATE Manufacturers and Suppliers

PipelinePharma has found 9 verified atracurium besylate manufacturers and suppliers from our global list of sellers. The pharmaceutical drug is available for sale in different forms such as injection, solution for injection, ampoules from manufacturers in various countries including China, India, Indonesia, Ukraine, Egypt. Being a global B2B pharmaceutical online marketplace, Pipelinepharma is structured so as to simplify pharmaceutical deals by providing you with an intuitive interface that is easy to engage with. The selection of atracurium besylate offerings can be narrowed down with the use of filters and easily weighed against one another according to medication prices and commercial terms.